Patents Represented by Attorney, Agent or Law Firm Elias J. Lambiris, Esq.
  • Patent number: 5885304
    Abstract: The present invention relates to a detergent composition, detergent additive as well as a method of oxidizing a substrate which comprises contacting the substrate with a composition which includes an enzyme selected from the group consisting of laccase, catechl oxidase, monophenol monooxygenase, and bilirubin oxidase and an enhancing agent.
    Type: Grant
    Filed: April 16, 1997
    Date of Patent: March 23, 1999
    Assignee: Novo Nordisk A/S
    Inventors: Palle Schneider, Anders Hjelholt Pedersen
  • Patent number: 5866391
    Abstract: The present invention relates to Aspergillus porphobilinogen synthases and isolated nucleic acid fragments comprising nucleic acid sequences encoding the porphobilinogen synthases as well as nucleic acid constructs, vectors, and recombinant host cells comprising the nucleic acid sequences. The invention also relates to methods of producing the porphobilinogen synthases.
    Type: Grant
    Filed: June 9, 1997
    Date of Patent: February 2, 1999
    Assignee: Novo Nordisk Biotech, Inc.
    Inventors: Aubrey Jones, Joel R. Cherry
  • Patent number: 5866357
    Abstract: A method is disclosed for obtaining limited specific hydrolysis of proteins using a Glu/Asp specific protease to produce peptides with C-terminal Glu or Asp. The protease is obtained from Bacillus licheniformis, has a mass of about 23,600, is inhibited by diisopropyl fluoride but not by phenylmethane sulfonylfluoride, and has a pH of maximal activity between 6.5 and 10.0. The proteins are treated with the protease at neutral pH and the reaction terminated by raising the temperature above 70.degree. C. or lowering the pH below 5.0 to obtain the hydrolysate. The process may include a second protease which is specific for Arg/Lys, and produces peptides with C-terminal Arg or Lys.
    Type: Grant
    Filed: August 31, 1992
    Date of Patent: February 2, 1999
    Assignee: Novo Nordisk A/S
    Inventors: Claus Dambmann, Steen Bennike Mortensen, Peter Budtz, Svend Eriksen
  • Patent number: 5795760
    Abstract: The present invention relates to isolated nucleic acid constructs containing a sequence encoding a Myceliophthora laccase, and the laccase proteins encoded thereby.
    Type: Grant
    Filed: September 29, 1997
    Date of Patent: August 18, 1998
    Assignees: Novo Nordisk A/S, Novo Nordisk Biotech, Inc.
    Inventors: Randy Michael Berka, Stephen H. Brown, Feng Xu, Palle Schneider, Karen M. Oxenb.o slashed.ll, Dorrit A. Aaslyng
  • Patent number: 5795855
    Abstract: This invention relates to methods of oxidizing a substrate in the presence of a laccase or a laccase related enzyme and an enhancing agent. More specifically, the invention relates to a method of bleaching of dye in solutions, to a method of inhibiting the transfer of a textile dye from a dyed fabric to another fabric when said fabrics are washed together in a wash liquor, to a method of bleaching of lignin-containing material, in particular bleaching of pulp for paper production, to a method of treatment of waste water from pulp manufacturing, and to a method of enzymatic polymerization and/or modification of lignin or lignin containing material.
    Type: Grant
    Filed: December 21, 1995
    Date of Patent: August 18, 1998
    Assignee: Novo Nordisk A/S
    Inventors: Palle Schneider, Anders Hjelholt Pedersen
  • Patent number: 5763187
    Abstract: The present invention relates to a modified bacterial donor cell useful in conjugation, the cell containing i) a plasmid comprising a DNA construct encoding the polypeptide of interest, and at least one cis-acting DNA sequence required for the transfer of said plasmid by conjugation in the presence of a trans-acting mobilizing element, and ii) at least one DNA sequence encoding said trans-acting mobilizing element, wherein the donor cell has a reduced capacity, relative to a parent cell, of producing a bactericidal agent which kills or prevents growth in a population of recipient cells.
    Type: Grant
    Filed: January 17, 1997
    Date of Patent: June 9, 1998
    Assignee: Novo Nordisk Biotech, Inc.
    Inventors: Alan P. Sloma, William R. Widner
  • Patent number: 5763254
    Abstract: The present invention relates to isolated and purified cellulose- or hemicellulose-degrading enzymes, comprising a catalytically active domain, a carbohydrate binding domain and a linking B region which operably links the catalytically active domain and the carbohydrate binding domain, wherein the carbohydrate binding domain has the following core sequence: ##STR1## wherein the enzyme is endogenous to a strain of a fungus other than Trichoderma or Phanerochaete.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 9, 1998
    Assignee: Novo Nordisk A/S
    Inventors: Helle Fabricius Woldike, Fred Hagen, Carsten Mailand Hjort, Sven Hastrup
  • Patent number: 5750388
    Abstract: The present invention relates to isolated nucleic acid constructs containing a sequence encoding a Scytalidium laccase, and the laccase proteins encoded thereby.
    Type: Grant
    Filed: November 15, 1996
    Date of Patent: May 12, 1998
    Assignee: Novo Nordish Bio Tech, Inc
    Inventors: Randy Michael Berka, Sheryl Ann Thompson, Feng Xu
  • Patent number: 5741693
    Abstract: The present invention relates to proteases obtained from a strain of Bacillus sp. AC13, and having (a) an apparent molecular weight of approximately 30 kD as determined by SDS-PAGE; (b) an isoelectric point of approximately 9.3 as determined by isoelectric focusing on LKB Ampholine PAG plates; (c) a pH optimum above 10 determined at 25.degree. C. with casein as substrate; (d) a temperature optimum in the range of 45.degree.-55.degree. C. determined at pH 9.5 with casein as substrate; and (e) immunochemical properties identical or partially identical to those of a protease derived from Bacillus sp. AC13, NCIMB No. 40482.
    Type: Grant
    Filed: November 30, 1994
    Date of Patent: April 21, 1998
    Assignee: Novo Nordisk A/S
    Inventors: Helle Outtrup, Claus Dambmann, Arne Agerlin Olsen, Henrik Bisg.ang.rd-Frantzen, Martin Schulein
  • Patent number: 5721260
    Abstract: The present invention relates to novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which a substituted alkyl chain forms part of the N-substituent or salts therefor, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation.
    Type: Grant
    Filed: April 4, 1996
    Date of Patent: February 24, 1998
    Assignee: Novo Nordisk A/S
    Inventors: Rolf Hohlweg, Knud Erik Andersen, Tine Krogh J.o slashed.rgensen, Peter Madsen, Henrik Sune Andersen
  • Patent number: 5721135
    Abstract: The present invention relates to a rapid automated device for identifying biologically active substances by their effect on living cells which includes a flow chamber defined by a bottom wall with a plane optical surface through which the content of the chamber can be monitored and a ring shaped wall having an edge adjacent the plane optical surface leaving a gap between the edge and optical surface wherein the width of the gap allows liquid but not matrix to pass. The flow chamber also including an inlet through which fluids can be transported into the chamber and a device to control the distance between the edge and the optical surface wherein the matrix is momentarily allowed to pass.
    Type: Grant
    Filed: July 6, 1995
    Date of Patent: February 24, 1998
    Assignee: Novo Nordisk A/S
    Inventors: Ole Thastrup, Kurt Scudder, Jaromir Ruzicka
  • Patent number: 5712292
    Abstract: The present invention relates to novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which a substituted alkyl chain forms part of the N-substituent or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation.
    Type: Grant
    Filed: October 18, 1995
    Date of Patent: January 27, 1998
    Assignee: Novo Nordisk A/S
    Inventors: Knud Erik Andersen, Uffe Bang Olsen, Hans Petersen, Frederik Christian Gr.o slashed.nvald, Ursula Sonnewald, Tine Krogh J.o slashed.rgensen, Henrik Sune Andersen
  • Patent number: 5707668
    Abstract: The present invention relates to a process of preparing a spread and the use of an enzyme in the production of a spread. The process of preparing a spread includes the following steps: a) the aqueous phase, which includes protein, is treated with an enzyme capable of enhancing the viscosity of the aqueous phase, b) the pH-value is adjusted to 4.8 to 6.0, c) the aqueous phase or emulsion is heated to between 60.degree. C. and 100.degree. C. for a period of time, d) the aqueous phase or the emulsion is tempered to a temperature between 30.degree. C. and 50.degree. C., e) the tempered aqueous phase is mixed with the fat phase and tempered to between 30.degree. C. and 50.degree. C. until an emulsion is formed, f) the emulsion is crystallized to form a spread. The steps in the process may be performed in the sequence steps a), b), c), d) e), f) or a), b), d), e), c), d), f).
    Type: Grant
    Filed: February 12, 1997
    Date of Patent: January 13, 1998
    Assignee: Novo Nordisk A/S
    Inventor: Lars Peter Andersen
  • Patent number: 5707858
    Abstract: This invention relates to an improved cellulase treatment of cellulosic fabrics to improve fabric quality with respect to handle and appearance without loss of fabric wettability. Cellulosic fabrics are subjected to two treatments with cellulase. The resulting fabric has a soft and smooth feel and reduced pilling.
    Type: Grant
    Filed: June 15, 1995
    Date of Patent: January 13, 1998
    Assignee: Novo Nordisk A/S
    Inventors: Garrett A. Screws, Gitte Pedersen
  • Patent number: 5705376
    Abstract: The present invention relates to a gene encoding an ascomycete or deuteromycete carboxypeptidase Y gene, and host cells modified so as to produce reduced amounts of carboxypeptidase.
    Type: Grant
    Filed: February 28, 1996
    Date of Patent: January 6, 1998
    Assignee: Novo Nordisk Biotech, Inc.
    Inventors: Debbie Sue Yaver, Sheryl Ann Thompson
  • Patent number: 5700914
    Abstract: The present invention describes a method for controlled activation and degradation of FVII during purification whereby a solution of Factor VII is subjected to a number of chromatographic purification steps wherein Zn.sup.++ is present in at least one of the purification steps.The present invention also describes a method for controlled activation and degradation of FVII wherein a solution of FVII is applied to a number of anion exchange and immunoaffinity columns.
    Type: Grant
    Filed: May 28, 1995
    Date of Patent: December 23, 1997
    Assignee: Novo Nordisk A/S
    Inventors: Tony J.o slashed.rgensen, Anders Hjelholt Pedersen
  • Patent number: 5696148
    Abstract: The present invention relates to therapeutically active indole compounds, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in treating diseases in the central nervous system related to the metabotropic glutamate receptor system.
    Type: Grant
    Filed: November 18, 1996
    Date of Patent: December 9, 1997
    Assignee: Novo Nordisk A/S
    Inventors: Jane Marie Lundbech, Anders Kanstrup
  • Patent number: 5693510
    Abstract: The present invention relates to a gene encoding an ascomycete or deuteromycete carboxypeptidase Y gene, and host cells modified so as to produce reduced amounts of carboxypeptidase.
    Type: Grant
    Filed: February 28, 1996
    Date of Patent: December 2, 1997
    Assignee: Novo Nordisk Biotech, Inc.
    Inventors: Debbie Sue Yaver, Sheryl Ann Thompson
  • Patent number: 5693649
    Abstract: The present invention relates to novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which a substituted alkyl chain forms part of the N-substituent or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation.
    Type: Grant
    Filed: October 18, 1995
    Date of Patent: December 2, 1997
    Assignee: Novo Nordisk A/S
    Inventors: Knud Erik Andersen, Uffe Bang Olsen, Hans Petersen, Frederik Christian Gr.o slashed.nvald, Ursula Sonnewald, Tine Krogh J.o slashed.rgensen, Henrik Sune Andersen
  • Patent number: RE35822
    Abstract: The present invention relates to therapeutically active azacyclic compounds, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful as stimulants of the cognitive function of the forebrain and hippocampus of mammals and especially in the treatment of Alzheimer's disease, severe painful conditions and glaucoma.
    Type: Grant
    Filed: December 20, 1996
    Date of Patent: June 9, 1998
    Assignee: Novo Nordisk A/S
    Inventors: Per Sauerberg, Prebert H. Olesen, Charles H. Mitch